ORIJINAL ARAŞTIRMA
Kalça Adduktor Spastisitesi Olan Serebral Palsili Çocuklarda Botulinum Toksin-A Enjeksiyonu: Retrospektif Bir Çalışma
Botulinum Toxin-A Injection for Hip Adductor Spasticity in Children with Cerebral Palsy: A Retrospective Study
Received Date : 20 Mar 2021
Accepted Date : 27 Apr 2021
Available Online : 05 Apr 2021
Esra SARIGEÇİLİa, Melek SEZGİNb, Ünzüle HANBABAb, Didem DERİCİ YILDIRIMc,
Çetin OKUYAZd
aClinic of Pediatric Neurology, Adana City Training and Research Hospital, Adana, TURKEY
bDepartment of Physical Medicine and Rehabilitation, Mersin University Faculty of Medicine, Mersin, TURKEY
cDepartment of Biostatistics, Mersin University Faculty of Medicine, Mersin, TURKEY
dDepartment of Pediatric Neurology, Mersin University Faculty of Medicine, Mersin, TURKEY
Doi: 10.31609/jpmrs.2021-83191 - Makale Dili: EN
J PMR Sci. 2021;24(3):277-83
ÖZET
Amaç: Kalça adduktor kas spastisitesi olan serebral palsili (SP) çocuklarda
botulinum toksin-A’nın klinik ve radyolojik etkinliğini araştırmak.
SP intrauterin ya da erken infantil dönemde meydana gelen hareket ve postür
bozukluğuna yol açan santral sinir sisteminin nonprogressive bir hastalığıdır.
Gereç ve Yöntemler: Çalışma retrospektif olarak dizayn edildi.
Kalça adduktor kas spastisitesi olması sebebi ile 1 yıl süresince düzenli
BoNT-A enjeksiyonu uygulanan hastalar belirlendi. Klinik değerlendirme
için, dizler arası mesafe, modifiye Asworth skalası (MAS) ve kaba motor
fonksiyon sınıflandırma sistemi (KMFSS) hasta dosyalarından kaydedildi.
Radyolojik değerlendirme anterior-posterior pelvis radyografisinde asetabular
indeks (AI) ve kollo-diafizer açı (KDA) ölçümü yapılarak belirlendi.
Bulgular: Çalışmaya dâhil edilen 20 hastanın ortalama yaşları (erkek: 12,
kız: 8) 84,8±20,9 aydı (minimum-maksimum: 48-120 ay). 7 hasta diplejik,
7 hasta kuadriplejik ve 6 hasta mix tip SP’idi. Hastaların MAS ve KMFSS
skorları ilk enjeksiyondan sonraki 3. ve 12. ayda büyük ölçüde azaldı (sağ
p:0,007 sol p:0,005 ve p:0,002 idi). Benzer şekilde, 3. ve 12. ayda dizler
arası mesafe de giderek arttı (p<0,001). Ancak radyolojik değerlendirmede
AI ve KDA’da anlamlı düzelme görülmedi (p>0,05). Sonuç: Bu çalışmada,
kalça adduktor kas spastisitesi olan SP’li çocuklarda seri BoNT-A enjeksiyonunun
klinik bir düzelme sağladığı ve radyolojik olarak ise progressif
kalça dislokasyonunu önlediği gösterilmiştir.
Anahtar Kelimeler: Serebral palsi; kalça adduktor kas; spastisite; botulinum toksin-A; çocuklar
ABSTRACT
Objective: To assess clinical and radiological effectiveness
of botulinum neurotoxin-A (BoNT-A) injection in children with cerebral
palsy (CP) with spasticity in the hip adductor muscles. CP is a nonprogressive
central nervous system disease that occurs in the intrauterine or early
infantile period that leads to posture or motor dysfunction and activity and
movement-limitation. Material and Methods: This study was designed as
a retrospective. Patients who received BoNT-A injections consecutively during
one year due to spasticity in bilateral hip adductor muscles were identified.
For clinical evaluation, distance between the knees, Modified Ashworth
Scale (MAS), and Gross Motor Function Classification System (GMFCS)
scores were recorded from the patient files. Radiological evaluation was
performed by measuring acetabular index (AI) and collo-diaphyseal angle
(CDA) in the A/P pelvis radiographs available in the patient registry system.
Results: The mean age of 20 patients (boys:12, girls:8) included in the study
was 84.8±20.9 months (minimum-maximum: 48-120 months). Seven patients
had diplegic, 7 patients quadriplegic and 6 patients mixed type involvement.
The MAS and GMFCS scores of the patients were found to be
decreased significantly at the third and twelfth month after the first injection
compared to pre-treatment (right p:0.007, left p:0.005 and p:0.002, respectively).
Similarly, the distance between knees had increased statistically at
the third and twelfth month (p<0.001). However, in the radiological evaluation,
AI and CDA measurements were not statistically different after 3
months and 12 months compared to pre-treatment (p>0.05). Conclusion:
This study demonstrated that sequential BoNT-A injections may provide
clinical improvement and prevent radiological progression of the hip in children
with CP with bilateral hip adductor spasticity.
Keywords: Cerebral palsy; hip adductor muscle; spasticity; and botulinum Neurotoxin-A; children
REFERENCES
- Bax M, Goldstein M, Rosenbaum P, et al; Executive committee for the definition of cerebral palsy. Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol. 2005;47:571-6. [Crossref] [PubMed]
- Sankar C, Mundkur N. Cerebral palsy-definition, classification, etiology and early diagnosis. Indian J Pediatr. 2005;72:865-8. [Crossref] [PubMed]
- Serdaroğlu A, Cansu A, Ozkan S, et al. Prevalence of cerebral palsy in Turkish children between the ages of 2 and 16 years. Dev Med Child Neurol. 2006;48:413-6. [Crossref] [PubMed]
- Shrader MW, Wimberly L, Thompson R. Hip surveillance in children with cerebral palsy. J Am Acad Orthop Surg. 2019;27:760-8. [Crossref] [PubMed]
- Howard CB, McKibbin B, Williams LA, et al. Factors affecting the incidence of hip dislocation in cerebral palsy. J Bone Joint Surg Br. 1985;67(4):530-2. [Crossref] [PubMed]
- Lonstein JE, Beck K. Hip dislocation and subluxation in cerebral palsy. J Pediatr Orthop. 1986;6:521-6. [Crossref] [PubMed]
- Terjesen T. Development of the hip joints in unoperated children with cerebral palsy: a radiographic study of 76 patients. Acta Orthop. 2006;77:125-31. [Crossref] [PubMed]
- Ramstad K, Jahnsen R, Skjeldal OH, et al. Characteristics of recurrent musculoskeletal pain in children with cerebral palsy aged 8 to 18 years. Dev Med Child Neurol. 2011;53: 1013-8. [Crossref] [PubMed]
- Graham HK. Painful hip dislocation in cerebral palsy. Lancet. 2002;359:907-8. [Crossref] [PubMed]
- Laplaza FJ, Root L, Tassanawipas A, et al. Femoral torsion and neck-shaft angles in cerebral palsy. J Pediatr Orthop. 1993;13:192-9. [PubMed]
- Sharrard WJ, Allen JM, Heaney SH. Surgical prophylaxis of subluxation and dislocation of the hip in cerebral palsy. J Bone Joint Surg Br. 1975;57:160-6. [Crossref] [PubMed]
- Tilton AH. Management of spasticity in children with cerebral palsy. Semin Pediatr Neurol. 2004;11:58-65. [Crossref] [PubMed]
- Koog YH, Min BI. Effects of botulinum toxin A on calf muscles in children with cerebral palsy: a systematic review. Clin Rehabil. 2010;24: 685-700. [Crossref] [PubMed]
- Ryll U, Bastiaenen C, De Bie R, et al. Effects of leg muscle botulinum toxin A injections on walking in children with spasticity-related cerebral palsy: a systematic review. Dev Med Child Neurol. 2011;53:210-6. [Crossref] [PubMed]
- Pin TW, Elmasry J, Lewis J. Efficacy of botulinum toxin A in children with cerebral palsy in Gross Motor Function Classification System levels IV and V: a systematic review. Dev Med Child Neurol. 2013;55:304-13. [Crossref] [PubMed]
- Shrader M.W., Crea B. Hip Dysplasia in Children with Cerebral Palsy. Cerebral Palsy. 2018;27:201-8. [Crossref]
- Kalen V, Bleck EE. Prevention of spastic paralytic dislocation of the hip. Dev Med Child Neurol. 1985;27:17-24. [Crossref] [PubMed]
- Miller F, Slomczykowski M, Cope R, et al. Computer modeling of the pathomechanics of spastic hip dislocation in children. J Pediatr Orthop. 1999;19:486-92. [Crossref] [PubMed]
- Coutinho dos Santos LH, Bufara Rodrigues DC, Simões de Assis TR, et al. Effective results with botulinum toxin in cerebral palsy. Pediatr Neurol. 2011;44:357-63. [Crossref] [PubMed]
- Linder M, Schindler G, Michaelis U, et al. Medium-term functional benefits in children with cerebral palsy treated with botulinum toxin type A: 1-year follow-up using gross motor function measure. Eur J Neurol. 2001;8:120-6. [Crossref] [PubMed]
- Mall V, Heinen F, Kirschner J, et al. Evaluation of botulinum toxin A therapy in children with adductor spasm by gross motor function measure. J Child Neurol. 2000;15:214-7. [Crossref] [PubMed]
- Aydil S, Akpinar FM, Akpinar E, et al. Effectiveness of multilevel botulinum toxin a ınjection with ıntegrated treatment program on spasticity reduction in non-ambulatory young children with cerebral palsy. Med Princ Pract. 2019;28:309-14. [Crossref] [PubMed] [PMC]
- Mirska A, Kułak W, Okurowska-Zawada B, et al. Effectiveness of multiple botulinum toxin sessions and the duration of effects in spasticity therapy in children with cerebral palsy. Childs Nerv Syst. 2019;35:141-7. [Crossref] [PubMed] [PMC]
- Alexander C, Elliott C, Valentine J, et al. Muscle volume alterations after first botulinum neurotoxin A treatment in children with cerebral palsy: a 6-month prospective cohort study. Dev Med Child Neurol. 2018;60:1165-71. [Crossref] [PubMed]
- Eek MN, Himmelmann K. No decrease in muscle strength after botulinum neurotoxin-a injection in children with cerebral palsy. Front Hum Neurosci. 2016;10:506. [Crossref] [PubMed] [PMC]
- Boyd RN, Dobson F, Parrott J, et al. The effect of botulinum toxin type A and a variable hip abduction orthosis on gross motor function: a randomized controlled trial. Eur J Neurol. 2001;8:109-19. [Crossref] [PubMed]
- Yang Y, Porter D, Zhao L, et al. How to judge pelvic malposition when assessing acetabular index in children? Three simple parameters can determine acceptability. J Orthop Surg Res. 2020;15:12. [Crossref] [PubMed] [PMC]
- Shore BJ, Martinkevich P, Riazi M, et al; CHOP Investigative Team. Reliability of radiographic assessments of the Hip in cerebral palsy. J Pediatr Orthop. 2019;39:e536-e541. [Crossref] [PubMed]
- Flynn JM, Miller F. Management of hip disorders in patients with cerebral palsy. J Am Acad Orthop Surg. 2002;10:198-209. [Crossref] [PubMed]
- Jung NH, Heinen F, Westhoff B, Doederlein L, Reissig A, Berweck S, Linder-Lucht M, Schandelmaier S, Mall V; German Abo study group. Hip lateralisation in children with bilateral spastic cerebral palsy treated with botulinum toxin type A: a 2-year follow-up. Neuropediatrics. 201;42:18-23. [Crossref] [PubMed]
- Pidcock FS, Fish DE, Johnson-Greene D, et al. Hip migration percentage in children with cerebral palsy treated with botulinum toxin type A. Arch Phys Med Rehabil. 2005;8:431-5. [Crossref] [PubMed]
- Placzek R, Deuretzbacher G, Meiss AL. Treatment of lateralisation and subluxation of the hip in cerebral palsy with Botulinum toxin A: preliminary results based on the analysis of migration percentage data. Neuropediatrics. 2004;35:6-9. [Crossref] [PubMed]